Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.

Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT.

ESMO Open. 2018 Jul 12;3(5):e000364. doi: 10.1136/esmoopen-2018-000364. eCollection 2018.

2.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA.

J Clin Oncol. 2018 Jun 15:JCO2018777672. doi: 10.1200/JCO.2018.77.7672. [Epub ahead of print]

PMID:
29906251
3.

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program.

Quinn GP, Pentz RD, Muñoz-Antonia T, Boyle TA, Schabath MB, Pratt CL, Shaffer A, Duarte LF, Bowman-Curci M, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Williams CC, Haura EB.

Patient Educ Couns. 2018 Apr;101(4):703-710. doi: 10.1016/j.pec.2017.11.014. Epub 2017 Nov 28.

4.

A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE.

Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.

5.

Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.

Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiappori AA, Schabath MB, Reuther GW, Dutil J, Garcia M, Ventosilla-Villanueva R, Vera-Valdivia L, Yabar-Berrocal A, Motta-Guerrero R, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD.

J Thorac Oncol. 2017 Dec;12(12):1851-1856. doi: 10.1016/j.jtho.2017.08.019. Epub 2017 Sep 11.

PMID:
28911955
6.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

7.

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.

Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Allard B, Stagg J, Antonia SJ.

Neoplasia. 2017 Jul;19(7):530-536. doi: 10.1016/j.neo.2017.02.004. Epub 2017 Jun 3.

8.

Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months.

Riccio AM, Mauri P, De Ferrari L, Rossi R, Di Silvestre D, Benazzi L, Chiappori A, Dal Negro RW, Micheletto C, Canonica GW.

Clin Transl Allergy. 2017 Mar 9;7:6. doi: 10.1186/s13601-017-0143-1. eCollection 2017.

9.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI.

J Clin Oncol. 2016 Dec;34(34):4079-4085. Epub 2016 Oct 31.

PMID:
27863201
10.

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.

Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD.

Oncotarget. 2016 Dec 13;7(50):82254-82265. doi: 10.18632/oncotarget.12672.

11.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164. Epub 2016 Sep 30.

12.

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.

Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.

13.

Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers.

Kubal T, Letson DG, Chiappori AA, Springett GM, Shimkhada R, Tamondong Lachica D, Peabody JW.

BMJ Open. 2016 Sep 13;6(9):e012312. doi: 10.1136/bmjopen-2016-012312.

14.

Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis.

Hembree TN, Teer JK, Hakam A, Chiappori AA.

Cancer Control. 2016 Jan;23(1):61-6.

PMID:
27009459
15.

A phase I study of indoximod in patients with advanced malignancies.

Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ.

Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216.

16.

Molecular diagnosis and precision medicine in allergy management.

Riccio AM, De Ferrari L, Chiappori A, Ledda S, Passalacqua G, Melioli G, Canonica GW.

Clin Chem Lab Med. 2016 Nov 1;54(11):1705-1714. doi: 10.1515/cclm-2016-0007. Review.

17.

CD4(+)CD25(high)CD127(-) regulatory T-cells in COPD: smoke and drugs effect.

Chiappori A, Folli C, Balbi F, Caci E, Riccio AM, De Ferrari L, Melioli G, Braido F, Canonica GW.

World Allergy Organ J. 2016 Feb 12;9:5. doi: 10.1186/s40413-016-0095-2. eCollection 2016.

18.

Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.

Raj S, Bui MM, Springett G, Conley A, Lavilla-Alonso S, Zhao X, Chen D, Haysek R, Gonzalez R, Letson GD, Finkelstein SE, Chiappori AA, Gabrilovitch DI, Antonia SJ.

Sarcoma. 2015;2015:614736. doi: 10.1155/2015/614736. Epub 2015 Dec 31.

19.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators.

Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. Erratum in: Lancet Oncol. 2017 Mar;18(3):e134.

20.

Propelling Immunotherapy Combinations Into the Clinic.

Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ.

Oncology (Williston Park). 2015 Dec;29(12):990-1002. Review.

21.

RRM1, ERCC1 and TS1 Immunofluorescence Expression in Leiomyosarcoma: A Tissue Microarray Study with Clinical Outcome Correlation Analysis.

Zheng SD, Bui K, Chiappori A, Bepler G, Bui MM.

Pathol Oncol Res. 2016 Jul;22(3):477-82. doi: 10.1007/s12253-015-0021-x. Epub 2015 Nov 26.

PMID:
26612755
22.

Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?

De Ferrari L, Chiappori A, Bagnasco D, Riccio AM, Passalacqua G, Canonica GW.

Expert Rev Respir Med. 2016;10(1):29-38. doi: 10.1586/17476348.2016.1111763. Epub 2015 Nov 13. Review.

PMID:
26566089
23.

Biomarkers and severe asthma: a critical appraisal.

Chiappori A, De Ferrari L, Folli C, Mauri P, Riccio AM, Canonica GW.

Clin Mol Allergy. 2015 Oct 1;13:20. doi: 10.1186/s12948-015-0027-7. eCollection 2015. Review.

24.

Lung cancer mutations and use of targeted agents in Hispanics.

Cress WD, Chiappori A, Santiago P, Muñoz-Antonia T.

Rev Recent Clin Trials. 2014;9(4):225-32. Review.

25.

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH.

Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2.

26.

Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.

Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):828-33. doi: 10.1016/j.ijrobp.2014.07.023. Epub 2014 Sep 9.

PMID:
25216856
27.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.

Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.

PMID:
25153538
28.

Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.

Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ, Chiappori AA.

Lung Cancer. 2014 Oct;86(1):14-21. doi: 10.1016/j.lungcan.2014.07.014. Epub 2014 Jul 27.

29.

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreahling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S.

Clin Cancer Res. 2014 Mar 15;20(6):1644-55. doi: 10.1158/1078-0432.CCR-13-2235. Epub 2014 Jan 15.

30.
31.

Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.

Tanvetyanon T, Creelan BC, Chiappori AA.

Cancer Control. 2014 Jan;21(1):32-9. Review.

PMID:
24357739
32.

Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB.

J Thorac Oncol. 2014 Jan;9(1):121-5. doi: 10.1097/JTO.0000000000000027.

33.

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A.

J Immunother. 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237.

34.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.

J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.

35.

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D.

Cancer Immunol Immunother. 2013 May;62(5):909-18. doi: 10.1007/s00262-013-1396-8. Epub 2013 Apr 16.

36.

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ.

J Transl Med. 2013 Mar 8;11:62. doi: 10.1186/1479-5876-11-62.

37.

Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.

Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA.

Clin Nucl Med. 2013 Mar;38(3):175-82. doi: 10.1097/RLU.0b013e318279ffdf.

38.

Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.

Hall RD, Gray JE, Chiappori AA.

Cancer Control. 2013 Jan;20(1):22-31. Review.

PMID:
23302904
39.

Immunotherapy treatments for small-cell lung cancer: past, present and future.

Whitehurst M, Chiappori A.

Lung Cancer Manag. 2013;2(6):517-525.

40.

Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells.

Lanzilli G, Traggiai E, Braido F, Garelli V, Folli C, Chiappori A, Riccio AM, Bazurro G, Agazzi A, Magnani A, Canonica GW, Melioli G.

Immunol Lett. 2013 Jan;149(1-2):62-7. doi: 10.1016/j.imlet.2012.11.009. Epub 2012 Dec 1.

PMID:
23206888
41.

COPD treatment: real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion.

Folli C, Chiappori A, Pellegrini M, Garelli V, Riccio AM, De Ferrari L, Braido F, Canonica GW.

Pulm Pharmacol Ther. 2012 Oct;25(5):371-6. doi: 10.1016/j.pupt.2012.06.009. Epub 2012 Jul 2.

PMID:
22766315
42.

Salbutamol: how does it enter smooth muscle cells?

Chiappori A, Folli C, Riccio AM, Caci E, Descalzi D, De Ferrari L, Ingrassia E, Nicolini G, Canonica GW.

Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):541-6.

PMID:
22697089
43.

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.

Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A, Canonica GW.

Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):475-84.

PMID:
22697079
44.

Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

Gray J, Cubitt CL, Zhang S, Chiappori A.

Cancer Biol Ther. 2012 Jun;13(8):614-22. doi: 10.4161/cbt.19848. Epub 2012 Jun 1.

45.

Cellular immunotherapy for soft tissue sarcomas.

Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A.

Immunotherapy. 2012 Mar;4(3):283-90. doi: 10.2217/imt.12.3. Review.

46.

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.

Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS.

Br J Cancer. 2012 Feb 28;106(5):839-45. doi: 10.1038/bjc.2012.21. Epub 2012 Feb 14.

47.

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.

Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.

48.

Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.

Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C.

J Thorac Oncol. 2011 Mar;6(3):553-8. doi: 10.1097/JTO.0b013e31820b8d88.

49.

Targeted cancer therapy: dendritic cell metabolism.

Gray J, Chiappori A.

Ther Deliv. 2011 Feb;2(2):133-6. No abstract available.

PMID:
22833938
50.

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A.

Int J Cancer. 2011 Oct 15;129(8):1963-9. doi: 10.1002/ijc.25843. Epub 2011 Mar 25.

Supplemental Content

Loading ...
Support Center